DDMS

Biosynthesis of 20-HETE from arachidonic acid by the cytochrome P450 4A (CYP450 4A) isoforms is an important component of vascular homeostasis, especially in renal circulation. DDMS is a mechanism-based, irreversible inhibitor that has about 10-fold selectivity for the CYP4A2 enzyme which predominantly synthesizes 20-HETE in the mammalian kidney. DDMS administration in whole anesthetized rats (10 mg/kg) largely ablates the hypotension and vasodilation induced by nitric oxide donors such as NONOates.Formal Name: 12,12-dibromo-N-(methylsulfonyl)-11-dodecenamide. CAS Number: 206052-03-1. Synonyms: Dibromo-dodecenyl-methylsulfimide. Molecular Formula: C13H23Br2NO3S. Formula Weight: 433.2. Purity: >98%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 30 mg/ml, DMF:PBS (pH 7.2) (1:10): .5 mg/ml, DMSO: 20 mg/ml, Ethanol: 30 mg/ml. lambdamax: 203 nm. SMILES: BrC(=CCCCCCCCCCC(=O)NS(=O)(=O)C)Br. InChi Code: InChI=1S/C13H23Br2NO3S/c1-20(18,19)16-13(17)11-9-7-5-3-2-4-6-8-10-12(14)15/h10H,2-9,11H2,1H3,(H,16,17). InChi Key: BDCZFOHEQGRTBW-UHFFFAOYSA-N.